Clinical Trials Logo

Clinical Trial Summary

The purpose of study is to investigate if yoga exercise improve life quality and immune status in breast cancer patients after complete treatment (including surgery and / or radiotherapy and / or chemotherapy)


Clinical Trial Description

It is well-known that exercise promote immune regulation for better life quality. However, the mechanism for better immunity and life quality is not clear. We postulate that Ayurveda yoga might benefit breast cancer women with completion of operation and/or chemotherapy and radiotherapy. The benefits could be due to immune modulation, and improve health perception and life quality, and even potential decrease of cancer relapse.

The study patients will do yoga twice a week for 12 weeks. The study primary endpoints are 1) to improve personal health perception, 2) to improve life quality and 3) to enhance human immunity. The study secondary endpoint will follow up the immunity changes 3 months after the intervention.

We anticipate to reach the primary endpoints and to publish the primary results in one year, the secondary endpoint will complete in the second year. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT02243163
Study type Interventional
Source Chang Bing Show Chwan Memorial Hospital
Contact Shin-Mae Wang, MD.
Email wangznmg@gmail.com
Status Recruiting
Phase N/A
Start date May 2014
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT04290585 - Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography N/A
Terminated NCT02540330 - A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Phase 2
Completed NCT02005770 - Anesthesia and Circulating Tumor Cells in Breast Cancer Phase 4
Completed NCT01643148 - The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer N/A
Active, not recruiting NCT02942355 - Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Phase 2